Equities research analysts expect that Soleno Therapeutics, Inc. (NASDAQ:SLNO) will report ($0.08) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics reported earnings of ($0.16) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The firm is expected to announce its next earnings report on Monday, August 9th.
On average, analysts expect that Soleno Therapeutics will report full year earnings of ($0.32) per share for the current fiscal year. For the next year, analysts anticipate that the firm will post earnings of ($0.27) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Soleno Therapeutics.
Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Wednesday, May 5th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.03).
Shares of Soleno Therapeutics stock traded down $0.01 during trading on Friday, reaching $1.14. The company’s stock had a trading volume of 8,948 shares, compared to its average volume of 2,519,277. Soleno Therapeutics has a 52-week low of $0.93 and a 52-week high of $3.36. The company has a market cap of $90.89 million, a P/E ratio of -2.74 and a beta of 0.43. The firm has a 50-day simple moving average of $1.13.
Institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC bought a new position in shares of Soleno Therapeutics in the 4th quarter worth about $25,000. Credit Suisse AG bought a new position in shares of Soleno Therapeutics in the 4th quarter worth about $36,000. Warberg Asset Management LLC bought a new position in shares of Soleno Therapeutics in the 1st quarter worth about $38,000. UBS Group AG increased its stake in shares of Soleno Therapeutics by 269.6% in the 1st quarter. UBS Group AG now owns 36,976 shares of the company’s stock worth $47,000 after acquiring an additional 26,971 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of Soleno Therapeutics by 159.0% in the 1st quarter. Barclays PLC now owns 49,804 shares of the company’s stock worth $63,000 after acquiring an additional 30,576 shares in the last quarter. Institutional investors own 41.03% of the company’s stock.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program.
Further Reading: What is a conference call?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.